NM23-H1 expression of head and neck squamous cell carcinoma in association with the response to cisplatin treatment

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7392-7405

  Wang, Yi Fen ^a,b   Chang, Chun Ju ^c   Chiu, Jen Hwey ^b   Lin, Chin Ping ^d   Li, Wing Yin ^a,b   Chang, Shyue Yih ^a   Chu, Pen Yuan ^a,b   Tai, Shyh Kuan ^a,b   Chen, Yu Jen ^b,d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cisplatin; Head and neck squamous cell carcinoma (HNSCC); Metastasis; NM23 H1; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN A; CYCLIN E; CYCLIN E1; NUCLEOSIDE DIPHOSPHATE KINASE A; UNCLASSIFIED DRUG; NME1 PROTEIN, HUMAN; NUCLEOSIDE DIPHOSPHATE KINASE NM23; TUMOR MARKER;

ADULT; ARTICLE; BIOACCUMULATION; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CELL CYCLE S PHASE; CELL PROLIFERATION; CERVICAL METASTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG RESPONSE; ENZYME ACTIVITY; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METASTASIS; MOLECULAR CLONING; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; AGED; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HEAD AND NECK NEOPLASMS; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PROPORTIONAL HAZARDS MODELS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84907494459     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1912     Document Type: Article

References (58)

1. Pindborg JJ. Epidemiological studies of oral cancer. Int Dent J. 1977; 27:172-178.
2. Sankaranarayanan R. Oral cancer in India: an epidemiologic and clinical review. Oral Surg Oral Med Oral Pathol. 1990; 69:325-330.
3. Hsieh LL, Wang PF, Chen IH, Liao CT, Wang HM, Chen MC, Chang JT and Cheng AJ. Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese. Carcinogenesis. 2001; 22:1497-1503.
4. Zakrzewska JM. Fortnightly review: oral cancer. Bmj. 1999; 318:1051-1054.
5. Chen YK, Huang HC, Lin LM and Lin CC. Primary oral squamous cell carcinoma: an analysis of 703 cases in southern Taiwan. Oral Oncol. 1999; 35:173-179.
6. Wang YF, Chow KC, Chang SY, Chiu JH, Tai SK, Li WY and Wang LS. Prognostic significance of nm23-H1 expression in oral squamous cell carcinoma. Br J Cancer. 2004; 90:2186-2193.
7. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA and Sobel ME. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988; 80:200-204.
8. Boissan M and Lacombe ML. Learning about the functions of NME/NM23: lessons from knockout mice to silencing strategies. Naunyn Schmiedebergs Arch Pharmacol. 2011; 384:421-431.
9. Ferguson AW, Flatow U, MacDonald NJ, Larminat F, Bohr VA and Steeg PS. Increased sensitivity to cisplatin by nm23-transfected tumor cell lines. Cancer Res. 1996; 56:2931-2935.
10. Lizuka N, Miyamoto K, Tangoku A, Hayashi H, Hazama S, Yoshino S, Yoshimura K, Hirose K, Yoshida H and Oka M. Downregulation of intracellular nm23-H1 prevents cisplatin-induced DNA damage in oesophageal cancer cells: possible association with Na(+), K(+)-ATPase. Br J Cancer. 2000; 83:1209-1215.
11. Wang LS, Chow KC, Lien YC, Kuo KT and Li WY. Prognostic significance of nm23-H1 expression in esophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 2004; 26:419-424.
12. Bevilacqua G, Sobel ME, Liotta LA and Steeg PS. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res. 1989; 49:5185-5190.
13. Hirayama R, Sawai S, Takagi Y, Mishima Y, Kimura N, Shimada N, Esaki Y, Kurashima C, Utsuyama M and Hirokawa K. Positive relationship between expression of anti-metastatic factor (nm23 gene product or nucleoside diphosphate kinase) and good prognosis in human breast cancer. J Natl Cancer Inst. 1991; 83:1249-1250.
14. Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, Vives J, Cardesa A and Yague J. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. Cancer. 1994; 73:2913-2921.
15. Pavelic K, Kapitanovic S, Radosevic S, Bura M, Seiwerth S, Pavelic LJ, Unusic J and Spaventi R. Increased activity of nm23-H1 gene in squamous cell carcinoma of the head and neck is associated with advanced disease and poor prognosis. J Mol Med (Berl). 2000; 78:111-118.
16. Muller W, Schneiders A, Hommel G and Gabbert HE. Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis. Cancer. 1998; 83:2481-2487.
17. Wang YF, Chen JY, Chang SY, Chiu JH, Li WY, Chu PY, Tai SK and Wang LS. Nm23-H1 expression of metastatic tumors in the lymph nodes is a prognostic indicator of oral squamous cell carcinoma. Int J Cancer. 2008; 122:377-386.
18. Jarrett SG, Novak M, Dabernat S, Daniel JY, Mellon I, Zhang Q, Harris N, Ciesielski MJ, Fenstermaker RA, Kovacic D, Slominski A and Kaetzel DM. Metastasis suppressor NM23-H1 promotes repair of UV-induced DNA damage and suppresses UV-induced melanomagenesis. Cancer Res. 2012; 72:133-143.
19. Conery AR, Sever S and Harlow E. Nucleoside diphosphate kinase Nm23-H1 regulates chromosomal stability by activating the GTPase dynamin during cytokinesis. Proc Natl Acad Sci U S A. 2010; 107:15461-15466.
20. Fan Z, Beresford PJ, Oh DY, Zhang D and Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003; 112:659-672.
21. Chakravarti D and Hong R. SET-ting the stage for life and death. Cell. 2003; 112:589-591.
22. Kaetzel DM, Zhang Q, Yang M, McCorkle JR, Ma D and Craven RJ. Potential roles of 3'-5' exonuclease activity of NM23-H1 in DNA repair and malignant progression. J Bioenerg Biomembr. 2006; 38:163-167.
23. Steeg PS, Horak CE and Miller KD. Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res. 2008; 14:5006-5012.
24. Lionello M, Blandamura S, Lovato A, Franchella S, Giacomelli L, Ottaviano G, Stellini E, Staffieri A and Marioni G. A high nuclear nm23-H1 expression is associated with a better prognosis in elderly patients with laryngeal carcinoma. Acta Otolaryngol. 2013; 133:874-880.
25. Kim SH, Lee SY, Park HR, Sung JM, Park AR, Kang S, Kim BG, Choi YP, Kim YB and Cho NH. Nuclear localization of Nm23-H1 in head and neck squamous cell carcinoma is associated with radiation resistance. Cancer. 2011; 117:1864-1873.
26. He G, Kuang J, Khokhar AR and Siddik ZH. The impact of S-and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. Gynecol Oncol. 2011; 122:402-409.
27. Iizuka N, Hirose K, Noma T, Hazama S, Tangoku A, Hayashi H, Abe T, Yamamoto K and Oka M. The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma. Br J Cancer. 1999; 81:469-475.
28. Boissan M, De Wever O, Lizarraga F, Wendum D, Poincloux R, Chignard N, Desbois-Mouthon C, Dufour S, Nawrocki-Raby B, Birembaut P, Bracke M, Chavrier P, Gespach C and Lacombe ML. Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res. 2010; 70:7710-7722.
29. Yoon JH, Singh P, Lee DH, Qiu J, Cai S, O'Connor TR, Chen Y, Shen B and Pfeifer GP. Characterization of the 3' → 5' exonuclease activity found in human nucleoside diphosphate kinase 1 (NDK1) and several of its homologues. Biochemistry. 2005; 44:15774-15786.
30. Wang X, Wong SC, Pan J, Tsao SW, Fung KH, Kwong DL, Sham JS and Nicholls JM. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res. 1998; 58:5019-5022.
31. Caligo MA, Cipollini G, Fiore L, Calvo S, Basolo F, Collecchi P, Ciardiello F, Pepe S, Petrini M and Bevilacqua G. NM23 gene expression correlates with cell growth rate and S-phase. Int J Cancer. 1995; 60:837-842.
32. Ota I, Ohnishi K, Takahashi A, Yane K, Kanata H, Miyahara H, Ohnishi T and Hosoi H. Transfection with mutant p53 gene inhibits heat-induced apoptosis in a head and neck cell line of human squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2000; 47:495-501.
33. Jung H, Seong HA and Ha H. NM23-H1 tumor suppressor and its interacting partner STRAP activate p53 function. J Biol Chem. 2007; 282:35293-35307.
34. Choudhuri T, Murakami M, Kaul R, Sahu SK, Mohanty S, Verma SC, Kumar P and Robertson ES. Nm23-H1 can induce cell cycle arrest and apoptosis in B cells. Cancer Biol Ther. 2010; 9:1065-1078.
35. Li Y, Nie CJ, Hu L, Qin Y, Liu HB, Zeng TT, Chen L, Fu L, Deng W, Chen SP, Jia WH, Zhang C, Xie D and Guan XY. Characterization of a novel mechanism of genomic instability involving the SEI1/SET/NM23H1 pathway in esophageal cancers. Cancer Res. 2010; 70:5695-5705.
36. Chowdhury D, Beresford PJ, Zhu P, Zhang D, Sung JS, Demple B, Perrino FW and Lieberman J. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell. 2006; 23:133-142.
37. Lombardi D. Commentary: nm23, a metastasis suppressor gene with a tumor suppressor gene aptitude? J Bioenerg Biomembr. 2006; 38:177-180.
38. Choudhuri T, Verma SC, Lan K and Robertson ES. Expression of alpha V integrin is modulated by Epstein-Barr virus nuclear antigen 3C and the metastasis suppressor Nm23-H1 through interaction with the GATA-1 and Sp1 transcription factors. Virology. 2006; 351:58-72.
39. Kaul R, Murakami M, Lan K, Choudhuri T and Robertson ES. EBNA3C can modulate the activities of the transcription factor Necdin in association with metastasis suppressor protein Nm23-H1. J Virol. 2009; 83:4871-4883.
40. Bedrosian I, Lu KH, Verschraegen C and Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene. 2004; 23:2648-2657.
41. Smith ML and Seo YR. Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations. Anticancer Res. 2000; 20:2537-2539.
42. Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M, Gorringe KL, Smyth GK and Bowtell DD. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One. 2010; 5:e15498.
43. Igawa M, Rukstalis DB, Tanabe T and Chodak GW. High levels of nm23 expression are related to cell proliferation in human prostate cancer. Cancer Res. 1994; 54:1313-1318.
44. Boissan M, Wendum D, Arnaud-Dabernat S, Munier A, Debray M, Lascu I, Daniel JY and Lacombe ML. Increased lung metastasis in transgenic NM23-Null/SV40 mice with hepatocellular carcinoma. J Natl Cancer Inst. 2005; 97:836-845.
45. Volm M, Koomagi R, Mattern J and Efferth T. Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer. 2002; 87:251-257.
46. Davidson B, Risberg B, Berner A, Nesland JM, Trope CG, Kristensen GB, Bryne M, Goscinski M, van de Putte G and Florenes VA. Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications. Gynecol Oncol. 2001; 83:249-256.
47. Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R, Sanchez JJ, Ballestin C, Diez A, Sanchez-Verde L, Alameda F and Sanchez-Cespedes M. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.Clin Cancer Res. 2004; 10:8486-8492.
48. Sozmen M, Tunca R and Dag Erginsoy S. Cyclin A expression is associated with apoptosis and mitosis in murine 3-methylcholanthrene-induced fibrosarcomas. Exp Toxicol Pathol. 2009; 61:41-49.
49. Ding H, Han C, Guo D, Wang D, Chen CS and D'Ambrosio SM. OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis. Int J Cancer. 2008; 123:2923-2930.
50. Curtis CD, Likhite VS, McLeod IX, Yates JR and Nardulli AM. Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue H1 and estrogen receptor alpha alters estrogen-responsive gene expression. Cancer Res. 2007; 67:10600-10607.
51. Suhardja AS, Kovacs KT and Rutka JT. Molecular pathogenesis of pituitary adenomas: a review. Acta Neurochir (Wien). 1999; 141:729-736.
52. Biliran H, Jr., Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH and Liao JD. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 2005; 11:6075-6086.
53. Wang MB, Yip HT and Srivatsan ES. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin. Laryngoscope. 2001; 111:982-988.
54. Ou Y, Ma L, Ma L, Huang Z, Zhou W, Zhao C, Zhang B, Song Y, Yu C and Zhan Q. Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells. Cancer Biol Ther. 2013; 14:45-55.
55. Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy B, Murphy GP, O'Sullivan B, Sobin LH and Yarbro JW. AJCC cancer staging manual. Thyroid gland Philadelphia: Lippincott Raven. 1997:59-64.
56. Chang CJ, Yin PH, Yang DM, Wang CH, Hung WY, Chi CW, Wei YH and Lee HC. Mitochondrial dysfunction-induced amphiregulin upregulation mediates chemo-resistance and cell migration in HepG2 cells. Cell Mol Life Sci. 2009; 66:1755-1765.
57. Chang CJ, Chiu JH, Tseng LM, Chang CH, Chien TM, Chen CC, Wu CW and Lui WY. Si-Wu-Tang and its constituents promote mammary duct cell proliferation by up-regulation of HER-2 signaling. Menopause. 2006; 13:967-976.
58. Chang CJ, Chiu JH, Tseng LM, Chang CH, Chien TM, Wu CW and Lui WY. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. Eur J Clin Invest. 2006; 36:588-596.